Cachexia, a systemic wasting condition, is considered a late consequence of diseases,
including cancer, organ failure, or infections, and contributes to significant morbidity and …

Despite tremendous gains in the molecular understanding of exocrine pancreatic cancer,
the prognosis for this disease remains very poor, largely because of delayed disease …

Abstract Cachexia affects 50–80% of patients with cancer and accounts for 20% of cancer-
related death, but the underlying mechanism driving cachexia remains elusive. Here we …

Most patients with pancreatic adenocarcinoma (PDAC) suffer cachexia; some do not. To
model heterogeneity, we used patient-derived orthotopic xenografts. These phenocopied …

A priority in cancer research is to innovate therapies that are not only effective against tumor
progression but also address comorbidities such as cachexia that limit quality and quantity …

Background Weight loss and homeostatic disturbances of both energy and protein balances
are characteristics of several illnesses including cancer, heart failure, and chronic kidney …

Background Sarcopenia is the loss of skeletal muscle mass and function that occurs with
advancing age and certain diseases. It is thought to have a negative impact on survival in …

Background Cachexia is frequent, deadly, and untreatable for patients with pancreatic ductal
adenocarcinoma (PDAC). The reproductive hormone and cytokine Activin is a mediator of …

Body composition has gained increasing attention in oncology in recent years due to fact
that sarcopenia has been revealed to be a strong prognostic indicator for survival across …

Cancer cachexia is a complex multifactorial syndrome marked by a continuous depletion of
skeletal muscle mass associated, in some cases, with a reduction in fat mass. It is …